Shares of major health insurers slid Monday as investors reacted to a Senate deal that ended the 40-day U.S. government shutdown but failed to extend subsidies under the Affordable Care Act (ACA).The agreement delays the contentious issue until December, raising uncertainty for millions of Americans who depend on the subsidies to afford health coverage.Health insurance stocks are trading lower as markets weighed the political impasse's impact on the sector.On Sunday, Reuters cited Trump’s Truth Social post, ...

DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) today announced the pricing of the previously announced private placement offering and has agreed to issue and sell $1.5 billion in aggregate principal amount of senior secured first lien notes due on November 15, 2032, which will bear interest at a rate of 5.500% per annum (the "first lien notes†), and $0.75 billion in aggregate principal amount of senior notes due November 15, 2033, which will bear interest at a rate of 6.000%. ...

来源：视频滚动新闻 美股周三早盘，跨国医疗服务巨头泰尼特健保(Tenet Healthcare，THC)股价小幅上扬，此前该公司将其 2025年EBITDA指引上调至45.7亿美元，主要受强劲的同店增长和运营效率推动。 ...

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: Tenet Healthcare raised its full-year financial forecast on Tuesday after posting third quarter results that showed year-over-year growth in revenue and adjusted earnings. It’s the second consecutive quarter Tenet has raised its financial forecast due to outperforming company expectations. The hospital operator now expects between $21.2 billion ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - Woolworths Group reported its first quarter sales results for the 2026 financial year, indicating that overall sales performance remains below expectations [1][2] Group Performance - The company acknowledged that changes have been implemented to enhance its offerings in various areas to address the sales performance issue [2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q ý Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2025 OR ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from __________ to Commission File Number: 1-7293 TENET HEALTHCARE CORPORATION (Exact name of Registrant as specified in its charter) Nevada (State of Incorporation) 95-255 ...

Financial Data and Key Metrics Changes - In Q3 2025, the company reported net operating revenues of $5.3 billion, with consolidated adjusted EBITDA growing 12% year-over-year to $1.1 billion, resulting in an adjusted EBITDA margin of 20.8%, a 170 basis points improvement from the previous year [5][11] - The company raised its full-year 2025 adjusted EBITDA guidance to a range of $4.47 billion to $4.57 billion, reflecting an increase of $445 million or 11% at the midpoint from initial guidance [7][15] - Free cash flow for Q3 was $778 million, totaling $2.16 billion year-to-date, which is a 22% increase over the same period last year [14] Business Line Data and Key Metrics Changes - The USPI segment generated $492 million in adjusted EBITDA, representing a 12% year-over-year growth, with same-facility revenues increasing by 8.3% [5][11] - The hospital segment's adjusted EBITDA grew 13% to $607 million, with same-store hospital admissions up 1.4% and revenue per adjusted admission increasing by 5.9% [6][12] Market Data and Key Metrics Changes - The company opened a new hospital facility in Port St. Lucie, Florida, aimed at expanding capacity in a rapidly growing area [6] - Exchange business accounted for 8.4% of total admissions and 7% of total consolidated revenues in Q3, showing a slight increase from Q2 [24][77] Company Strategy and Development Direction - The company is focusing on higher acuity services, which has led to improved margins and strong earnings growth [9] - The strategy includes continued M&A and de novo development, with a robust pipeline for future acquisitions [6][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's performance, citing healthy patient demand and stable operating conditions for 2026 [8][9] - There is uncertainty regarding enhanced premium tax subsidies and their impact on reimbursement and enrollment in exchanges, but management is prepared for various scenarios [8][9] Other Important Information - The company has invested nearly $300 million in M&A activities year-to-date and plans to continue this trend [6] - The company has no significant debt maturities until 2027, providing financial flexibility [14] Q&A Session Summary Question: Q4 guidance and utilization expectations - Management has not built in expectations for higher utilization due to exchange subsidies expiring, and they are confident in their capacity to meet typical demand [19][21] Question: CapEx inputs and allocation - The increase in CapEx is focused on clinical program infrastructure and high-acuity service offerings, with specific investments in cardiac care and surgical programs [26][28] Question: Free cash flow sustainability - Management highlighted improved cash collections and operational efficiencies as key drivers of free cash flow, emphasizing a focus on sustainability [30][32] Question: USPI Q4 guidance and growth - The implied Q4 guidance for USPI suggests year-over-year growth of over 8%, which is consistent with historical trends [35][36] Question: Labor environment and inflationary pressures - The labor environment remains strong, and management does not foresee significant changes or inflationary pressures impacting operations in 2026 [39][41] Question: Conifer's contribution and enrollment capabilities - Conifer is performing well, assisting with patient eligibility and enrollment, and is prepared to support potential changes in exchange enrollment timelines [45][47] Question: Service line performance in Q3 - Growth in USPI was driven by higher acuity services, with a noted recovery in GI services, while respiratory and infectious disease volumes were lower than expected [51][53] Question: DPP contribution and estimates for 2026 - The company recorded approximately $346 million in supplemental Medicaid programs in Q3, with $148 million being prior year adjustments [59][60] Question: Capital allocation and buyback strategy - The company remains active in share repurchases and is responsive to market conditions while continuing to pursue M&A opportunities [62][64] Question: Expense management and AI initiatives - The company is exploring opportunities for cost savings and efficiency improvements, including the use of advanced analytics and automation [66][68] Question: M&A environment for ASCs - The company continues to be a partner of choice in the ASC market, focusing on high-end specialties and maintaining a strong pipeline for growth [71][73]

Financial Data and Key Metrics Changes - In Q3 2025, the company reported net operating revenues of $5.3 billion, with consolidated adjusted EBITDA growing 12% year-over-year to $1.1 billion, resulting in an adjusted EBITDA margin of 20.8%, a 170 basis points improvement from the previous year [5][11] - The company raised its full-year 2025 adjusted EBITDA guidance to a range of $4.47 to $4.57 billion, reflecting an increase of $445 million, or 11% at the midpoint from initial guidance [7][15] - Free cash flow for Q3 was $778 million, totaling $2.16 billion year-to-date, which is a 22% increase over the same period last year [14] Business Line Data and Key Metrics Changes - The USPI segment generated $492 million in adjusted EBITDA, representing a 12% year-over-year growth, with same-facility revenues increasing by 8.3% [5][11] - The hospital segment's adjusted EBITDA grew 13% to $607 million, with same-store hospital admissions up 1.4% and revenue per adjusted admission increasing by 5.9% [6][12] Market Data and Key Metrics Changes - The company reported that exchange admissions accounted for 8.4% of total admissions and 7% of total consolidated revenues in Q3, indicating a slight increase from Q2 [24][77] - The company noted that the exchange business at USPI has less exposure compared to the hospital segment, with exchange patients exhibiting consumption patterns similar to Medicaid [22][72] Company Strategy and Development Direction - The company is focusing on higher acuity services, which has led to improved margins and strong earnings growth over the past few years [9] - The strategy includes continued investment in M&A and de novo development, with a robust pipeline for future growth [6][9] - The company plans to invest $875 to $975 million in capital expenditures in 2025, a $150 million increase at the midpoint over prior expectations [7][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's performance, citing healthy patient demand and stable operating conditions for 2026 [8][9] - There is uncertainty regarding enhanced premium tax subsidies and their impact on reimbursement and enrollment in exchanges, but management is optimistic about a potential compromise [8][21] - The company is committed to maintaining a deleveraged balance sheet and generating strong free cash flow [14][15] Other Important Information - The company recognized a $38 million pre-tax impact for Medicaid supplemental revenues related to prior years in Q3 2025, totaling $148 million year-to-date [13][59] - The company has no significant debt maturities until 2027 and reported $2.98 billion in cash on hand as of September 30, 2025 [14] Q&A Session Summary Question: Q4 guidance and utilization expectations - Management has not built in expectations for higher utilization due to exchange subsidies expiration and is confident in USPI's capacity to handle typical demand [19][21] Question: CapEx inputs and allocation - The increased CapEx is focused on clinical program infrastructure and high-acuity service offerings, with specific investments in cardiac care and surgical programs [26][28] Question: Free cash flow sustainability - Management highlighted improved cash collections and operational efficiencies as key drivers for sustainable free cash flow generation [30][32] Question: USPI Q4 guidance and growth expectations - The implied Q4 guidance reflects typical seasonal growth patterns, with no significant changes in business demand anticipated [35][36] Question: Labor environment and inflationary pressures - The labor environment remains strong, with no significant changes expected, and the company is managing inflationary pressures effectively [39][41] Question: Contribution from Conifer and enrollment services - Conifer is performing well, and the company is preparing to utilize its capabilities for potential enrollment needs if exchange subsidies expire [45][47] Question: Service line performance in Q3 - Growth in USPI was driven by higher acuity services, with some lower-than-expected volumes in respiratory and infectious disease areas noted on the hospital side [51][53] Question: DPP contribution and estimates for the year - The company recorded approximately $346 million in supplemental Medicaid programs in Q3, with $148 million being out-of-period [59][60] Question: Capital allocation and buyback strategy - The company remains focused on M&A and de novo strategies while being active in share repurchases, adjusting based on market conditions [62][64] Question: Expense management opportunities for 2026 - The company is exploring various opportunities for cost savings and efficiency improvements, including labor and supply management [66][68] Question: Impact of the WISER model on USPI - The company is preparing for potential changes in pre-authorization requirements under the WISER model, with a capable revenue cycle function in place [80][81] Question: Inpatient-only list removal impact - The potential removal of the inpatient-only list could benefit the USPI segment, but quantification of the impact is still under discussion [85][86]

Financial Data and Key Metrics Changes - In Q3 2025, net operating revenues were $5.3 billion, with consolidated adjusted EBITDA growing 12% year-over-year to $1.1 billion, resulting in an adjusted EBITDA margin of 20.8%, a 170 basis points improvement from the previous year [4][11] - The company raised its full-year 2025 adjusted EBITDA guidance to a range of $4.47 to $4.57 billion, reflecting an increase of $445 million, or 11% at the midpoint from initial guidance [6][14] - Free cash flow for 2025 is now expected to be in the range of $2.275 to $2.525 billion, with free cash flow after non-controlling interest projected at $1.495 to $1.695 billion, an increase of $250 million at the midpoint from previous guidance [7][16] Business Line Data and Key Metrics Changes - USPI's adjusted EBITDA grew 12% year-over-year to $492 million, with same-facility revenues increasing by 8.3% and total joint replacements in ASCs growing by 11% [4][11] - The hospital segment's adjusted EBITDA increased 13% to $607 million, with same-store hospital admissions up 1.4% and revenue per adjusted admission rising 5.9% [5][12] Market Data and Key Metrics Changes - The exchange business represented 8.4% of total admissions and 7% of total consolidated revenues in Q3, with a slight increase in total as a percent of admissions from Q2 [24][68] - The company noted healthy patient demand supporting same-store volume growth and a stable operating environment for 2026 [8][9] Company Strategy and Development Direction - The company is focusing on higher acuity services, which has led to improved margins and strong earnings growth [9][10] - There is a robust M&A and de novo activity, with 11 centers acquired and two new centers opened in Q3, emphasizing high-acuity procedures [5][6] - Capital expenditures for 2025 are expected to be between $875 million and $975 million, reflecting a $150 million increase at the midpoint over prior expectations [6][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's performance, citing strong same-store revenue growth, high patient acuity, and effective cost controls [11][14] - There is uncertainty regarding enhanced premium tax subsidies and their impact on reimbursement and enrollment in exchanges for 2026, but management remains optimistic about patient demand [8][9] Other Important Information - The company recognized a $38 million pre-tax impact for Medicaid supplemental revenues related to prior years in Q3 2025, totaling $148 million year-to-date [12][54] - The leverage ratio as of September 30 was 2.3 times EBITDA, indicating strong operational performance and financial discipline [13][14] Q&A Session Summary Question: Q4 guidance and utilization expectations - Management has not built in expectations for higher utilization due to exchange subsidies expiring, but they are prepared for typical demand increases in Q4 [19][20] Question: CapEx inputs and allocation - The increased CapEx is focused on clinical program infrastructure and growth strategies, particularly in high-acuity services [25][26] Question: Free cash flow sustainability - The company highlighted improved cash collections and operational efficiencies as key drivers for sustainable free cash flow [28][29] Question: ASC volumes and service line performance - Growth in ASC volumes was driven by higher acuity services, with healthy GI recovery noted in Q3 [46][48] Question: Contribution from DPP in provider taxes - The company recorded approximately $346 million in supplemental Medicaid programs in Q3, with $148 million being out-of-period [52][54] Question: M&A environment for ASCs - The company remains a partner of choice in the ASC market, focusing on high-end specialties and multi-specialty centers [64][66] Question: Impact of CMS WISER model - The company is prepared for changes in pre-authorization requirements and is confident in managing operational adjustments [69][70] Question: Inpatient-only list removal impact - The potential removal of the inpatient-only list could benefit the USPI segment, but quantification of the impact is still under discussion [73][74]